Pharma News

Novartis announces clinical collaboration to evaluate Bristol-Myers Squibb's novel immunotherapy in combination treatments for NSCLC

  • Posted on: 6 October 2014
  • By: PharmaTutor News

(6th October, 2014); Novartis announced today that it has entered into a clinical collaboration with Bristol-Myers Squibb Company to evaluate the safety, tolerability and preliminary efficacy of three molecularly targeted compounds in combination with Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab), in Phase I/II trials of patients with non-small cell lung cancer (NSCLC).

Broad spectrum antibiotics associated with obesity risk in 2 or less year old children

  • Posted on: 1 October 2014
  • By: PharmaTutor News

(1st October, 2014); Think before prescribing broad spectrum antibiotics in children below 2 years of age. Researchers from Philadelphia published a report on last Monday states that the use of broad-spectrum antibiotics by children before the age of 24 months was associated with increased risk of obesity in early childhood.

Apollo Hospitals and Sanofi Announce Collaboration to Provide an Integrated Care Program in India for People with Diabetes

  • Posted on: 30 September 2014
  • By: PharmaTutor News

(30th September, 2014; Business Wire India); Apollo Hospitals and Sanofi today announced their decision to collaborate on the expansion of Apollo Sugar Clinics, which provide integrated diabetes care programs in India. Through this collaboration, Apollo and Sanofi plan to leverage their respective expertise in diabetes to provide patients with access to comprehensive educational resources, treatment and care programs that can help patients better manage their diabetes. The first wave of this collaboration will focus on the establishment of 50 Apollo Sugar Clinics.

Fortis Wins Prestigious BMJ Award for Successful Antibiotic Review Program

  • Posted on: 30 September 2014
  • By: PharmaTutor News

(30th September, 2014; Business Wire India); Fortis Healthcare announced on last friday (26th sept) that Fortis Mulund, one of its major hospitals in Mumbai has been conferred the prestigious British Medical Journal (BMJ) Award for ‘The Medical Team of the Year 2014.’ The honour was bestowed on the hospital for its outstanding “Antibiotic Review Program – and Antibiotic Restriction Policy.”

Fortis Healthcare Wins the Prestigious Porter Prize 2014 for Value Based Healthcare

  • Posted on: 30 September 2014
  • By: PharmaTutor News

(30th September, 2014; Business Wire India); Fortis Healthcare has been awarded the prestigious 2014 ‘Porter Prize, for Value Based Healthcare’. The prize was given in recognition of the company’s outstanding performance in the industry and for redefining the idea of patient care and fundamentally challenging the economic models within the industry.

Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy

  • Posted on: 20 September 2014
  • By: PharmaTutor News

(20th September, 2014; Business Wire India); Boehringer Ingelheim obtains exclusive global rights for development and commercialisation of CureVac’s investigational therapeutic cancer vaccine CV9202CV9202 is based on CureVac’s mRNA technology (RNActive®) Clinical investigation of CV9202 will be initiated in at least two different lung cancer treatment settings, in combination with Boehringer Ingelheim’s afatinib* and in the chemo-radiation setting. The in-licensing of this investigational cancer compound adds a highly innovative new approach to Boehringer Ingelheim’s lung cancer development portfolio.

Australian Life Sciences & Health Care Mission visiting India

(17th September, 2014); A 12 member Australian Life Sciences & Health Care delegation is visiting India from 15 to 19 September. The business delegation is a flagship activity of the Australian Innovation Showcase in India 2014. This is an initiative of the Australian Trade Commission and the Australian Government to promote Australia’s world class research capability and innovative technologies, and to help develop new trade and investment opportunities.

Pages